MannKind Corporation, a company focused on the development and commercialization of therapeutic products for people living with endocrine and orphan lung diseases, announced that it has entered into an agreement with Zealand Pharma A/S to acquire V-Go for $10 million, with additional sales-based milestones plus the cost of certain inventory.
The acquisition of V-Go allows MannKind to expand its portfolio and strengthen its commitment to providing innovative mealtime diabetes solutions.
